A Phase III study of Solithromycin in patients with community-acquired pneumonia
Phase 3
- Conditions
- Community-acquired pneumonia
- Registration Number
- JPRN-jRCT2080223384
- Lead Sponsor
- Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1.Age: 20 years of age and older (at the time of obtaining informed consents)
2.Gender : Both
3.Inpatient/Outpatient status: Either
4.No history of hospitalization or hospitalization in a long-term care facility within 2 weeks before the onset of pneumonia
5.Confirmed clear infiltrative shadow by chest X-ray or CT within 48 hours prior to the first administration of the study drug
6.Signed the informed consent form by patients or patients' legal representatives
7.Others
Exclusion Criteria
1.Having improvement of clinical symptoms due to pneumonia by other systemic antibiotics
2.Having a history of allergy to macrolide or quinolone antibiotics
3.Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method